Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
Procedures are facilitated for marketing of domestically produced foreign pharmaceuticals
Successful U.S. IPO of Chinese EV brand suggests rising investor confidence, but regulatory risks still loom; Burberry wins trademark infringement and unfair competition lawsuit; and China proposes guidelines to it's lithium battery sector amid overcapacity concerns.
SAMR specifies details on collecting electronic evidence
Although CFIUS reviews have become more challenging for Chinese companies, transactions could still go ahead with a few tips in mind.
China lifts foreign investment restrictions on value-added telecommunications services
Na Wang and Yihui Liu, partners of Tian Yuan Law Firm, examine the Chinese securities regulator's key issues of concern with respect to overseas listings, and offer insights into the most recent regulatory trends
